Harbour BioMed is a global biopharmaceutical company developing innovative therapeutics for oncology and immunological diseases. The company's discovery and development programs are centered around its two patented fully human transgenic mouse platforms: (i) H2L2 – mice that generate two heavy-chain, two light chain antibodies; and (ii) HCAb – mice that generate novel “Heavy Chain Only” antibodies. |
Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October
To sponsor or exhibit contact:
Derek Cavanagh
+44 (0)207 092 1297
derek.cavanagh@terrapinn.com
To speak:
Joan Shutt
+44 (0)207 092 1134
joan.shutt@terrapinn.com